| 1 |
钱桂生. 肺癌不同病理类型发病率的变化情况及其原因[J/CD]. 中华肺部疾病杂志(电子版), 2011, 4(1): 1-5.
|
| 2 |
Masters GA, Johnson DH, Temin S. Systemic therapy for stage Ⅳ non-small-cell lung cancer: American society of clinical oncology clinical practice guideline update.[J]. J Oncol Pract, 2017, 33(30): 832-837.
|
| 3 |
Soria JC, Tan D, Chiari R, et al. First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study.[J]. Lancet, 2017, 389(10072): 917-929.
|
| 4 |
Tong B, Xu Y, Zhao J, et al. Prognostic significance of circulating tumor cells in non-small cell lung cancer patients undergoing chemotherapy[J]. Oncotarget, 2017, 8(49): 86615-86624.
|
| 5 |
Zhang Y, Wang Z, Hao X, et al. Clinical characteristics and response to tyrosine kinase inhibitors of patients with non-small cell lung cancer harboring uncommon epidermal growth factor receptor mutations[J]. Chinese J Cancer Res, 2017, 29(1): 18-24.
|
| 6 |
Meessenpinard M, Coupanec AL, Desforges M, et al. Pivotal role of receptor-interacting protein kinase 1 and mixed lineage kinase domain-like in neuronal cell death induced by the human neuroinvasive coronavirus OC43[J]. J Virol, 2017, 91(1): JVI.01513-16.
|
| 7 |
Harris PA, Berger SB, Jeong JU, et al. Discovery of a first-in-class receptor interacting protein 1 (RIP1) kinase specific clinical candidate (GSK2982772) for the treatment of inflammatory diseases[J]. J Med Chem, 2017, 60(4): 1247-1261.
|
| 8 |
Zhu-Ran Zhao, Wei-Dong Yu, Cheng Shi, et al. Correlation between receptor-interacting protein 140 expression and directed differentiation of human embryonic stem cells into neural stem cells[J]. Neural Regenerat Res, 2017, 12(1): 118-124.
|
| 9 |
Cruz JV, Serafim RB, Silva GMD, et al. Computational design of new protein kinase 2 inhibitors for the treatment of inflammatory diseases using QSAR, pharmacophore-structure-based virtual screening, and molecular dynamics[J]. J Molecul Model, 2018, 24(9): 225-230.
|
| 10 |
Cheng Z, Shan F, Yang Y, et al. CT characteristics of non-small cell lung cancer with epidermal growth factor receptor mutation: a systematic review and meta-analysis[J]. Bmc Med Imag, 2017, 17(1): 5-11.
|
| 11 |
Créquit P, Chaimani A, Yavchitz A, et al. Comparative efficacy and safety of second-line treatments for advanced non-small cell lung cancer with wild-type or unknown status for epidermal growth factor receptor: a systematic review and network meta-analysis[J]. Bmc Medicine, 2017, 15(1): 193-201.
|
| 12 |
Ko JJ, Tudor R, Li H, et al. Reasons for lack of referral to medical oncology for systemic therapy in stage Ⅳ non-small-cell lung cancer: comparison of 2003-2006 with 2010-2011.[J]. Current Oncol, 2017, 24(6)：e486-e493.
|
| 13 |
Kim DW, Tiseo M, Ahn MJ, et al. Brigatinib in patients with crizotinib-refractory anaplastic lymphoma kinase-positive non-small-cell lung cancer: A randomized, multicenter phase Ⅱ trial[J]. J Clin Oncol, 2017, 35(22): 2490-2498.
|
| 14 |
Pickl JM, Tichy D, Kuryshev VY, et al. Ago-RIP-Seq identifies Polycomb repressive complex I member CBX7 as a major target ofmiR-375 in prostate cancer progression：[J]. Oncotarget, 2016, 7(37): 59589-59603.
|
| 15 |
Koens K, Thomas R. "You know that′s a rip-off" ：policies and practices surrounding micro-enterprises and poverty alleviation in South African township tourism[J]. J Sustain Tourism, 2016: 1-14.
|
| 16 |
Kwa MQ, Huynh J, Aw J, et al. Receptor-interacting protein kinase 4 and interferon regulatory factor 6 function as a signaling axis to regulate keratinocyte differentiation.[J]. J Biol Chem, 2017, 289(45): 31077-31087.
|
| 17 |
Homer CR, Kabi A, Marinagarcía N, et al. A dual role for receptor-interacting protein kinase 2 (RIP2) kinase activity in nucleotide-binding oligomerization domain 2 (NOD2)-dependent autophagy[J]. J Biol Chem, 2016, 287(30): 25565-25576.
|
| 18 |
Feng X, Song Q, Yu A, et al. Receptor-interacting protein kinase 3 is a？predictor of survival and plays a tumor suppressive role in colorectal cancer[J]. Neoplasma, 2017, 62(4): 592-601.
|
| 19 |
Wang Q, Liu Z, Ren J, et al. Receptor-interacting protein kinase 3 contributes to abdominal aortic aneurysms via smooth muscle cell necrosis and inflammation[J]. Circul Res, 2017, 116(4): 600-608.
|
| 20 |
Suebsuwong C, Pinkas DM, Ray SS, et al. Activation loop targeting strategy for design of receptor-interacting protein kinase 2 (RIPK2) inhibitors[J]. Bioorgan Med Chem Letters, 2018, 28(4): 577-583.
|
| 21 |
Mccubbin AG, Wang X, Hu Y, et al. Isolation and characterization of kinase interacting protein 1, a pollen protein that interacts with the kinase domain of PRK1, a receptor-like kinase of petunia[J]. Plant Physiol, 2017, 126(4): 1480-1492.
|